Paeds · neurology-neurodisability-and-neuromuscular
Developmental regression and neurodegeneration
Also known as Developmental regression · Loss of milestones · Neurodegeneration in childhood · Progressive encephalopathy · Childhood dementia
A fellowship approach to the child who loses previously acquired developmental milestones. Recognise regression as a red flag, distinguish true progressive neurodegeneration from plateau and static loss, read the tempo and bedside pattern to generate a structured differential (epileptic encephalopathies, genetic and syndromic neurodegeneration, leukodystrophies, neurodegeneration with brain iron accumulation, and the acquired and treatable mimics - autoimmune encephalitis, subacute sclerosing panencephalitis, autistic regression, Rett syndrome), and drive a tiered neuro-investigation anchored on the developmental history, brain MRI, EEG and genomic sequencing - never accepting a degenerative label until the treatable causes have been actively excluded.
On this page & tools
Your progress
Saved locally on this device.
Practise this topic
Target exams
Red flags
Life stages
Care settings
Clinical exam formats
Board mappings
A toddler who was speaking in two-word phrases stops talking and begins to stumble, and a teenager with no past history arrives incoherent and twitching over a weekend. In both rooms the unifying question is the same: is this loss of skills a progressive disorder, and is there a therapy whose window is closing right now? The fellowship task is to convert that bedside worry into a structured, time-aware workup that does not forfeit a treatable cause to a comforting but wrong label such as autism, cerebral palsy, or behavioural change. [1] [9]
R · E · G · R · E · S · S
Anchor the whole topic with REGRESS - Recognise true loss of previously acquired skills (distinguish from plateau and static deficit), Exclude the treatable mimics early (autoimmune encephalitis, epileptic encephalopathy, GLUT1 deficiency), Group by bedside pattern (epilepsy, movement disorder, white-matter, basal-ganglia iron), Run a tiered workup (developmental history, MRI, EEG, then trio exome), Emergency protocol for acute decompensation and status epilepticus, Syndrome-specific and disease-modifying therapy matched to the cause, and Surveillance with structured transition to adult neurology and disability care. [1] [8]
Overview & Definition
The clinician's first act is to confirm what kind of developmental problem this is, because the word "regression" is used loosely and the distinction changes everything. Developmental delay means milestones are not being met on time. A plateau means the child has stopped gaining new skills but has not lost old ones. Neurological regression - the entity this page owns - means the child has lost previously acquired skills. Only regression carries the weight of a presumed progressive process, and only regression mandates the search for a neurodegenerative or otherwise treatable cause at speed. [1]
Why does losing skills carry so much more weight than simply being slow? Because a child whose trajectory was once higher and is now falling has something actively injuring the brain, whereas a child who is slow from the start or who has simply stopped climbing may have a static encephalopathy. The injury may be a structural neurodegenerative disease, an epileptic network disrupting cortical function, a synaptic autoimmune process, or a treatable metabolic defect - and the tempo of the fall is itself diagnostic. Acute or subacute regression, over days to weeks, raises the treatable and time-critical causes such as autoimmune encephalitis and metabolic decompensation; insidious regression, over months to years, raises the leukodystrophies, the storage disorders, and the neurodegenerations with brain iron accumulation. [1] [8]
What makes this group worth knowing in depth is that a meaningful and growing subset is treatable, and that treatment works best - or only - when it is begun before the brain injury becomes irreversible. The diagnostic label matters: calling a treatable autoimmune encephalitis a degenerative disorder forfeits the only chance of recovery, while calling a static unrecognised cerebral palsy a progressive regression subjects a family to a frightening and unnecessary workup. The history, not the single examination, settles which it is. [1]
You have read the opening of this topic. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References12Show ledgerHide ledger
- [1]Moeschler JB, Shevell M Comprehensive evaluation of the child with intellectual disability or global developmental delays. Pediatrics, 2014.PMID 25157020
- [2]Neul JL, Kaufmann WE, Glaze DG, Christodoulou J, Clarke AJ, Bahi-Buisson N, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol, 2010.PMID 21154482
- [3]Stefanatos GA. Regression in autistic spectrum disorders. Neuropsychol Rev, 2008.PMID 18956241
- [4]Stefanatos G. Changing perspectives on Landau-Kleffner syndrome. Clin Neuropsychol, 2011.PMID 21955111
- [5]Parikh S, Bernard G, Leventer RJ, van der Knaap MS, van Hove J, Pizzino A, et al. A clinical approach to the diagnosis of patients with leukodystrophies and genetic leukoencephelopathies. Mol Genet Metab, 2015.PMID 25655951
- [6]Schneider SA. Neurodegeneration with Brain Iron Accumulation. Curr Neurol Neurosci Rep, 2016.PMID 26739693
- [7]Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol, 2013.PMID 23290630
- [8]Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol, 2016.PMID 26906964
- [9]Cellucci T, Van Mater H, Graus F, Muscal E, Gallentine W, Klein-Gitelman MS, et al. Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. Neurol Neuroimmunol Neuroinflamm, 2020.PMID 31953309
- [10]Nosadini M, Thomas T, Eyre M, Anlar B, Armangue T, Benseler SM, et al. International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurol Neuroimmunol Neuroinflamm, 2021.PMID 34301820
- [11]Gascon GG Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-alpha in subacute sclerosing panencephalitis (SSPE): international multicenter study. J Child Neurol, 2003.PMID 14736075
- [12]Klepper J, Akman C, Armeno M, Auvin S, Cervenka M, Cross HJ, et al. Glut1 Deficiency Syndrome (Glut1DS): State of the art in 2020 and recommendations of the international Glut1DS study group. Epilepsia Open, 2020.PMID 32913944